Systematic Review

Efficacy of Pyrimethamine/Sulfadoxine versus Chloroquine for the Treatment of Uncomplicated Falciparum Malaria in Children Aged Under 5 Years

W Zheng¹, H Jiang², Z Xiong¹, Z Jiang³, H Chen¹

¹. Nanchang Center for Disease Control and Prevention, Nanchang, 330038, China
². Basic Medical College, Wuhan University, Wuhan, 430072, China
³. Huadong Research Institute for Medicine and Biotechnics, Nanjing, 210002, China

*Corresponding author: Email: zhengweiqing2001@163.com

(Received 20 Sep 2012; accepted 12 Jan 2013)

ABSTRACT

The children aged under 5 years from vast African areas badly suffer from falciparum malaria and many of them die of this disease. Therapeutic efficacy of anti-malaria drugs, especially pyrimethamine-sulfadoxine (PS) and chloroquine (CQ) to falciparum malaria is frequently evaluated and reported in recent 10 years. Unfortunately, to date, these widespread materials and researches have not been systematically collected and analyzed. In our study, two investigators were employed to widely and independently gather researches on efficacy of PS vs. CQ mono-therapy of falciparum malaria in children aged below 5 years in unpublished and published databases. Meta-analyses were conducted in categories of PS group and CQ group respectively. Pooled OR of PS vs. CQ was 0.11 (95%CI, 0.05-0.24). PS showed higher therapeutic efficacy to falciparum malaria in less-than-5-year children than CQ. Random model was chosen to analyze for the heterogeneity existence between different studies. Subgroup analyses were performed, but heterogeneity was still presented. Heterogeneity might be caused by different resistance of falciparum malaria to PS and CQ in different settings. Malaria type associated with parasite species, basic information of PS and CQ, and PS & CQ resistant malaria control measures were demonstrated and discussed respectively in detail in this article.

Keywords: Pyrimethamine/Sulfadoxine, Chloroquine, Malaria, Systematic review
Introduction

By far, the most important vector borne pathogen infection is malaria, due to one of several *Plasmodium* parasites which is transmitted by the bite of any one of the 50 species of *Anopheles* mosquitoes. Malaria is one of the most important diseases in the world. It exacts an enormous toll social life, medical costs and productivity in tropical regions of Africa, Asia, and Central and South Americas (1-2). In 10 top causes of death all over the world, malaria takes 5th place, following lower respiratory infections, diarrhoeal diseases, HIV/AIDS, and ischemic heart disease (3). Children aged below 5 years old frequently suffer from malaria with high morbidity and mortality. Many deaths in recent year belong to Angola, Benin, Burkina Faso, Cameroon, Central African Republic, Chad, Congo, Côte d’Ivoire, Democratic Republic of the Congo, Guinea, Guinea-Bissau, Mali, Mozambique, Niger, Nigeria, Sierra Leone, Uganda, and Zambia. Mortality in these countries which all come from Africa exceeds 100 persons per 100 000 population per year (4).

*Plasmodium* Species malaria prevalence
Malaria is caused by the protozoan *Plasmodium*, generally speaking, four species of which infect humans. These species are *P. falciparum*, *P. vivax*, *P. ovale* and *P. malariae*. However, the fifth malaria parasite *P. knowlesi* has raised public health concern (5). Almost all deaths and severe diseases are caused by *P. falciparum*. *Falciparum* is the predominant species in most endemic countries, exceptions being part of Southeast Asia and South America where *vivax* is more common (6-11). *Falciparum* malaria can form uncomplicated phase before severe malaria. If falciparum malaria was cured in uncomplicated phase, the mortality and morbidity of severe malaria will be reduced by a large margin.

Commonly used antimalarial drugs
Many drugs are applied to combat malaria. They are divided into six groups including aryl amino alcohols, 4-aminoquinolines, folate synthesis inhibitors, 8-aminoquinolines, antimicrobials, peroxides. The recent frequently recommended use happens in quinine (QN), mefloquine (MQ) of aryl amino alcohols, amodiaquine (AQ), chloroquine (CQ) of 4-aminoquinolines, pyrimethamine-sulfadoxine (PS) of folate synthesis inhibitors, primaquine (PQ) of 8-aminoquinolines, clindamycin (CL), doxycycline (D), tetracycline (T) of antimicrobials, and artemether-lumefantrine (AL), artesunate (AS), dihydroartemisinin (DHA) of peroxides. Two or more same or different kinds of them are recommended to use in combination, except CQ therapy of *vivax* malaria only, PS prevention of falciparum malaria in pregnancy and antimalarial drug mono-therapy of malaria in non-endemic regions (6-11). Among them, QN, AQ, CQ, PS and artemisinin (AN) are commonly used to treat global malaria. These drugs undergo different developmental history of application. QN had ever been the mainstream for treating severe malaria in children for several years. However, quinine-resistant malaria had been documented in Africa between 1980s and 1990s (12-15). Similarly, CQ had been the mainstay for malaria treatment for the past 40 years. Yet its use had been far and wide limited by the emergence and spread of CQ resistance in most endemic regions, and few countries were unaffected. In 1961, CQ resistance was firstly reported in Colombia (16). The resistance of Sudanese *P. falciparum* to CQ was first reported in Medani (17). In the mid 1970s, low-level resistance to CQ emerged in South Asia, and resistance to CQ increased in this region in the 1980s (18-19). By 1985, CQ resistance had affected 24 African countries (20). Since then, the proportion of cases of *P. falciparum* malaria which was at least partially resistant to CQ had risen steadily. In major areas, CQ was suspended to be a satisfactory first-line treatment for malaria and alternatives were chosen (21). Current options for the treatment of acute uncomplicated CQ-resistant *P. falciparum* infections in Africa include the use
of AQ or PS. This action have led to increasing use of alternative antimalarial drugs, notably PS. Although early studies show full sensitivity to PS, its efficacy for the treatment of symptomatic malaria in children declines after its use for antimalaria, raising concerns about its longevity for the treatment of malaria in children. However, most of malaria-endemic countries in Africa ill afford the more alternatives to CQ or PS (22). AQ is widely available in Africa and also already considered as a possible replacement for CQ in many parts of that continent (23-26). AN is invented in China, it is useful to control malaria. The use of artemisininin, its derivatives and artemisinin-based combination therapies is currently regarded as the best option for the treatment of malaria (27) and has been proposed as a strategy for tackling the problem of drug-resistant falciparum malaria. Nevertheless, cost implications have precluded the quick adoption of artemisinin-based regimes for controlling malaria in most African countries.

Although efficacy failure of PS and CQ to malaria is generally reported, PS & CQ are still extensively used to combat malaria for its low cost, especially in developing countries, such as countries from Africa. In this continent, CQ and PS remain the first-line and second-line therapies of uncomplicated malaria in some areas. In this study, we reviewed effect of PS vs. CQ on uncomplicated falciparum malaria in children aged below 5 years old in recent 10 years through meta-analysis. Before that, we looked back to some basic information about the invention, use history, and resistance of PS and CQ.

Basic information of PS

The antimalarial efficacy of sulfa drugs was discovered in 1940s. They inhibit the malarial parasites multiplication and development by blocking nucleic acid synthesis (28). In 1950, pyrimethamine was firstly invented by George Hitchings and his comrades at Burroughgs Wellcome in the United States. At its primary period of synthesis, it was synthesized as an anticancer agent, and then approved as a drug for the treatment of malaria disease in Britain in 1951 (29). Pyrimethamine and other sulfa drug sulfadoxine differently act on folic acid synthesis. Combination of them could synergistically improve the antimalarial efficacy between them. Use history and study of PS as an antimalarial drug were described per decade. During 1970-1979, PS for antimalarial was mainly reported in South East Asia, especially Thailand (30-31), and then in some African countries, such as Gambia (32). In 1980s, more and more countries used PS to combat malaria disease. These countries included South East countries such as Thailand (33), Burma(34), Cambodia (35) and Malaysia (36), African countries such as Zambia (37) and Tanzania (38), Latin America including Brazil (39) and Colombia (40), North America the US (41), Australia (42-43) and China (44). Malaria resistance was reported in South East Asia (33,45), Australia (42-43), Amazon (39) and east, west and central Africa. Utilization of PS plus other antimalarial drugs for the treatment of malaria parasites had been showed in a few countries (40,46). From 1990 to 1999, PS was frequently and widely recorded to use in vast Africa, such as Kenya (47), Mozambique (48), Zambia (49), Zimbabwe (50), Tanzania (51), Gabon (52), Gambia (53), Sudan and Nigeria (54). Some Asian countries also used PS to fight against malaria involving Philippine (55), Afghanistan (56), India (57) and Vietnam (58). Besides above malaria endemic area, a few Latin American countries (59) introduced PS to deal with malaria disease. Among this term, PS conferred resistance to malaria parasite in many of African countries (48,60). Combination of PS and other antimalarial drugs to fight against malaria was demonstrated in major areas (48,58, 61). Since 2000, PS plus more than one drugs have been developed to evaluate the antimalarial efficacy (22,62-63). PS resistance also has been reported in many places (64-66). Resistant mechanism (67-69) and the side effects of PS (70-71) have been widely studied and revealed.

Available at: http://ijpa.tums.ac.ir
Basic information of CQ

In 1891, dye methylene blue was discovered to be able to kill malaria parasites. During World War I, German scientist used it to synthesize the prototype of antimalarials. In 1932, other dye atabrine was employed to synthesize another antimalarial. German scientists found sontoquine in Tunis, and then sontoquine was modified to be chloroquine. Sontoquine and chloroquine were patented for prophylaxis and control of malaria in the United States in 1941. CQ could quickly control the symptom of susceptible malaria with minimal toxicity. In 1949, CQ was approved as antimalarial by the FDA (29).

CQ experienced different use history, resistance development from 1940 to present. At this period, pharmacological distribution of CQ between different populations was substantially researched. In 1940s, some papers reported good efficacy of CQ to control acute attacks of sporozoite-induced vivax malaria (72-73). In the periods of 1950-1959, African countries such as West Africa (74), Nigeria (75), and Congo (76) introduced CQ for controlling malaria. Good effect was displayed everywhere exception being in very few areas (77). During 1960-1969, CQ utilization extended for many areas, from Africa, South East Asia to Europe. However, malaria parasites developed widespread resistance to CQ (78-80). At this time, It was found that combination of CQ and table salt or a few other antimalarials could enhance the antimalarial efficacy of CQ (81). Between 1970 and 1979, CQ for antimalarial efficacy was useless because of high resistance development (82-85). Therefore, other antimalarial drugs were employed to combat CQ-resistant malaria (86-88), or CQ in combination with other drugs to control counterpart (89-90). Portion of resistant mechanism of rodent malaria was exposed. Rodent malaria resistance to CQ correlates with the presence of succinate dehydrogenase activity (91). From the researches among this period, we also know that inadequate CQ dose exposure will cultivate resistance of malaria parasite to CQ (92), CQ has effect on parasite biochemical activity, such as pigment clumping (93) and erythrocytic form (94), special population such as the infant (95-96), the pregnant and the person with other diseases (97) had different manifestation in CQ-resistant malaria, and side effects involving neuromyopathy and retinopathy from CQ were demonstrated (95,98-99). Among 1980-1989, rather-high-level and multi-plasmodium CQ resistant malaria parasites were presented (100-101). Imported CQ-resistant malaria cases were reported in some European countries (102-103). Other antimalarials including some new drugs halofantrine, tetracycline and desipramine were used for prevention or treatment of CQ resistant malaria (104-105). From vast drug efficacy evaluation for CQ resistant malaria, it was deduced that the judicious use of existing antimalarials, preferably in combinations, was in an attempt to delay the emergence of resistance; and on aggressive research effort aimed at identifying a new generation of antimalarial drugs. Possible causes of CQ resistance were described as ferriprotozophyrin IX receptor, calcium channel inhibitors and pH dependence (106-108). Besides above report or research, in this course we also understand that CQ could cause pruritus during the treatment of malaria (109-110). Between 1990 and 1999, mechanisms of action and resistance of CQ were widely and extendedly demonstrated. CQ resistance has no association with point mutation in the multidrug resistance 1 (pfdmr 1) gene (111) and pfdmr2 protein expression (112). The omega repetitive region of the P. falciparum CG2 gene acting as marker for CQ resistance should confirm under further research (113). After malaria infection, Plasmodium vivax-parasitized red blood cells (PRBCs) experiences oxidative stress, and this infection changes the anti-oxidative defense system of the host. When CQ introduced, the anti-oxidative defense system returns near normal levels (114). The remaining researches concerned about CQ resistant malaria treatment and side effects prevention and control (115-116). In 2000s, further research on mechanisms of CQ-resistant malaria was reported. Molecular marker for CQ-resistance was found as pfert gene (117).
Ferriprotoporphyrin IX (the CQ receptor) dimerization was induced after unmasked lipid promotion. The lipid could be unmasked by aging erythrocyte membrane ghosts from untreated or chloroquine-treated. The process indicated that CQ-induced unmasking of a lipid promoted ferriprotoporphyrin IX dimerization in malaria (118). Different Plasmodium species had different mechanisms of CQ resistance, that was supported by the example that the molecular events underlying P. vivax CQR differed from those in P. falciparum (119). From 2010 to present, it was reported in some cases that reemergence of CQ sensitive malaria had happened in some areas such as Kenya and Malawi (120-121). Contrary to the report that CQ resistance has no association with point mutation in the multidrug resistance 1 (pfmdr 1) gene and pfmdr2 protein expression, CQ clinical failures in P. falciparum malaria are associated with mutant Pfmdr-1 in Madagascar (122).

**PS versus CQ to combat uncomplicated falciparum malaria in under-5-year children in recent 10 years, meta-analysis**

Literature search was performed independently by two investigators (ZW, JH). Literature that we required were available in grey literature databases (unpublished literature) and published literature databases such as PubMed, British Medicine Association (BMA), Cambridge Science Abstract (CSA), Global Health, Conference Proceedings Citation Index (CPCI) and Wanfang data (a Chinese database with published paper and unpublished data that is mainly from conference proceedings).

Studies we screened occurred in Africa except a study performed in Myanmar of the Southeast Asia. These areas endured intense and widespread malaria incidence, especially among children aged less than 5 years. The total amount of 1911 patients, 919 for CQ group, 992 for PS group, with sample sizes ranging from 33 to 683, were included in 10 studies for analysis. 3 studies had less than 100 patients in sample size (123-125). More than 200 children were enrolled to participate in three studies (126-128). Patients of the rest studies recruited were from 100 to 200 (129-132). Axillary temperature of patients limited between 37.5 °C and 39.5 °C (or 40 °C) in 3 articles (123,126,130). The rest of studies had lower limit value of 37.5 °C without upper limit value (123,127-130,132). Parasite density in blood of patients who were selected varied from 2000/mL to 1000,000/mL in 5 studies (124, 126, 129-131). Parasite density of ≥1000/mL, 2000/mL were arranged respectively in Smith et al. and Basco et al. studies (123, 125). Stivanello et al. and Legros et al. set the same upper limit value of parasite density in enrollment patients at 100,000/mL and the different lower limit value, 1,000/mL for the former and 500/mL for the latter (128,132). The remaining studies had revealed that parasite density was in the range of 2000–20,000/mL (127).

There were 4 articles in which the clinicians or experimenter offered 1.25 mg/kg P + 0 mg/kg S body weight for PS group and 25mg/kg CQ for CQ group (128-129,131-132). In the other studies, 1.25 mg/kg P+25 mg/kg S and 25mg/kg CQ body weight were administrated in PS group and CQ group (123-127,130). All studies chose the oral method as route of administration (123-132). Days of follow-up were distributed into 4 groups in our screening studies, 28 days in 4 studies (127-129,131), 14 days in 4 studies (123-124, 126, 132), both 42 days and 21 days in one study (125,130) (Table 1). Total 241 of 992 patients with PS treatment had total failure in the trials in comparison with 572 of 919 patients with CQ treatment. The pooled odd ratio (OR) of PS vs. CQ mono-therapy of malaria in children aged <5 years in 10 screened studies was 0.11 (95% CI, 0.05-0.24). Compared with using CQ to treat malaria, PS had more effective treatment of this disease. The efficacy of PS treatment was significantly better than CQ treatment (Z=5.55, P<0.01). The other statistic indicator of 95% CI of OR whose value range excluded the cut-off value 1 also could be utilized to support this conclusion.
Table 1: Characteristics of the studies included in this meta-analysis of PS versus CQ mono-therapy for the treatment of uncomplicated falciparum malaria in children with the age under 5 years

| Reference              | Setting         | No. of population | Age               | Axillary temperature | Parasite density (/microliter) | Dose of drug received per child | Follow-up time interval |
|------------------------|-----------------|-------------------|-------------------|----------------------|--------------------------------|---------------------------------|------------------------|
| Guthmann et al.        | Angola          | 79CQ, 79PS        | 6-59 months       | ≥37.5°C              | 2000-100 000                   | 1.25mg/kg P +0mg/kg S 25mg/kg CQ | 28 days                |
| Grandesso et al.       | Chad            | 73CQ, 93PS        | 6-59 months       | ≥37.5°C              | 2000-100 000                   | 1.25mg/kg P +0mg/kg S 25mg/kg CQ | 28 days                |
| Basco et al.           | Cameroon        | 33CQ, 64PS        | less than 5 years | ≥37.5°C -39.5°C      | ≥2000                          | 1.25mg/kg P +25 mg/kg S 25mg/kg CQ | 14 days                |
| Smithuis et al.        | Myanmar         | 15CQ, 19PS        | less than 5 years | ≥37.5°C              | ≥1000                          | 1.25mg/kg P +25 mg/kg S 25mg/kg CQ | 42 days                |
| Menard et al.          | Central Africa  | 22CQ, 57PS        | 6-59 months       | ≥37.5°C              | 2000-100 000                   | 1.25mg/kg P +25mg/kg S 30mg/kg CQ | 14 days                |
| Kazadi et al.          | Congo           | 350CQ,308PS       | 6-59 months       | 37.5°C -39.5°C       | 2000-100 000                   | 1.25mg/kg P +25 mg/kg S 30mg/kg CQ | 14 days                |
| Radigués et al.        | Mali            | 110CQ, 100PS      | 6-59 months       | ≥37.5°C              | 2000-20 000                    | 1.25mg/kg P +25 mg/kg S 30mg/kg CQ | 28 days                |
| Abacassamo et al.      | Mozambique      | 85 CQ, 83 PS      | 6-59 months       | 37.5°C-40°C          | 2000–100 000                   | 25mg/kg S 30mg/kg CQ          | 21 days                |
| Stivanello et al.      | Sudan           | 114CQ, 103PS      | 6-59 months       | ≥37.5°C              | 1000–100 000                   | 1.25mg/kg P +0mg/kg S 25mg/kg CQ | 28 days                |
| Legros et al.          | Uganda          | 53 CQ, 64 PS      | 6-59 months       | ≥37.5°C              | 500–100 000                    | 1.25mg/kg P +0mg/kg S 25mg/kg CQ | 14 days                |

Nevertheless, the heterogeneity of these studies occurred (Chi²=71.72, P<0.1; I²=87%) (Fig. 1). The random model was borrowed to calculate and design the combined data from ten studies (Fig. 1). Following the meta-analysis regulation, if the heterogeneity among different studies existed, the subgroup analyses should be used for interpreting the effect difference among subgroups. We conducted the subgroup analyses in term of setting, parasite density, follow-up and drug regime. The subgroups analyses also displayed the heterogeneity between the studies. No reason could be found to explain rationality of the heterogeneity. Combined data from different studies was useless due to the heterogeneity. We transferred to tell therapeutic efficacy of PS vs. CQ to treat malaria disease one by one. ORs of PS vs. CQ efficacy against malaria in ten studies ranged from 0 to 0.43 (123-132). The lowest OR of PS vs. CQ for the treatment of malaria occurred in Cameroon with value of 0 (95%CI, 0-0.05), highest in Republic of Central Africa with value of 0.43 (95% CI, 0.15-1.22) (123-124). ORs of two studies went beyond 0.33, whose 95%CI included threshold value 1 denoting PS vs. CQ efficacy insignificant difference (124-125) (view Fig. 1, two lines crossed the central vertical line which represented null hypothesis). The remaining ORs in eight studies changed between 0 and 0.3 (Fig. 1) (123,126-132)(Fig. 1).


**Discussion and prospective**

Many studies reported different effect of PS vs. CQ for fighting against malaria. Some studies showed PS and CQ all had good effect on malaria, some denoted PS moderate efficacy to malaria, and other studies supported mild or little effect of PS and CQ on malaria. Judged from single paper or a study, we could not conclude the real efficacy of PS vs. CQ to combat malaria because of published bias. Until now, only a study for meta-analysis had revealed comparison of PS vs. CQ efficacy for the treatment of malaria in pregnant women and children. This study more concentrated on PS vs. CQ efficacy to women. Children’s age did not refer in this study (133). Our meta-analysis and systematic review firstly evaluated the efficacy of PS vs. CQ for the treatment of uncomplicated malaria in children with the age < 5 years. In our study, we screened the objective studies in 340 studies on PS and CQ used for the treatment of malaria disease from PubMed, BMA, CPCI, CSA, Globe Health and Wanfang databases. 10 qualified studies were selected with PS vs. CQ mono-therapy of malaria in less-than-five-year children.

The screened studies were controlled clinical trials, not randomized controlled trials. Drugs were randomly assigned to the enrolled patients from clinicians or experimenter. Nonetheless, we could not find that these study designs included allocation concealment and random sample. There was only one study following blind method using random number. Sample size should be calculated scientifically in a good study design. Most of our screened studies were performed well in sample size calculation regarding of precision, type I error risk, estimated value (failure rate) and loss to follow-up. Blood smear test for parasite density and PCR test for reinfection or recrudescence in late clinical failure/response were aided to assess end/surrogate point of PS vs. CQ effect on children patients. Good laboratory test really reflected the valid clinical response to drugs in patients. Some of our recruited studies involved laboratory quality management. In a word, our enrolled studies designs were not seriously conducted except sample size calculation.

Patients who were characterized by loss to follow-up, reinfection, PCR results inconclusive, or other factors which affected to reflect real efficacy of PS vs. CQ to malaria, were absolutely withdrawn. Total withdrawal didn’t
exceed 10% of enrolled patients. Patient individuals were recruited to well test efficacy of PS vs. CQ against malaria. Clinical response of PS vs. CQ to malaria was evaluated by percent of total failure in all patients. Recommended by WHO, anti-malaria drugs response to malaria are subgrouped by total failure which is equal to sum of clinical failure, early treatment failure and late treatment failure (or late clinical failure and late parasitological failure), and adequate clinical and parasitological response (134). Synthetic individuals of total failure and adequate clinical and parasitological response produce total patients. Different response could be assessed by follow-up days, sign and laboratory test. We pooled the data in ten studies for meta-analysis. PS had better efficacy than CQ for treating malaria through meta-analysis. Meanwhile, heterogeneity displayed between different studies. Although we stratified different studies and analyzed, heterogeneity also showed. Therefore, OR and other indicators calculated with pooled data was useless. So, we employed systematic review to conduct analysis one by one. Following the rule of sensitivity analysis, we should exclude the studies with small samples and the special studies with large samples. ORs of remaining studies were less than 0.33. All 95%CI in ORs excluded threshold value 1. Hence, we can conclude that PS has more effect than CQ on malaria regardless of its study sites. Nevertheless, the comparative effect of PS vs. CQ in different sites was significantly differently demonstrated. It is implied in our review that different-level drug resistance in different places resulted in PS or CQ having different efficacy to malaria. Malaria is widely resistant to the first line anti-malaria CQ in African countries, South East Asia and Latin America because of the long-time application for combating malaria (135-141). PS is the second-line drug for controlling malaria. Some countries find its good efficacy to treat malaria (142-144). Some malaria resistance to PS is shown in other countries (145-148). Different areas have different efficacy and resistant level in PS and CQ monotherapy of malaria. If PS and CQ were used to fight against malaria in an area, history of application and resistant level of two drugs in this area should be systematically supervised and surveyed. Generally speaking, we should consider the first use of PS and CQ to deal with malaria. The other anti-malaria drugs such as AQ, AL, AN, PQ and their derivatives or analogues are secondly utilized for PS and CQ treatment failure in malaria control. Endemic malaria commonly breaks out in undeveloped countries where economy is poor, resource is short of availability, and malnutrition presents here and there. Dearer drugs for vastly curing malaria in these countries are unreasonable. Cheaper drugs—eg, CQ and PS are easily acceptable. Absolute priority must be given to CQ treatment in an area where it isn’t used before. Otherwise, we can resort to PS. Therefore, CQ and PS are the first consideration for therapy of malaria although severe resistance occurs in some areas. Nonetheless, application of CQ and PS which have no efficacy to malaria because of resistance should be stopped quickly and widely. The more consumption, the more wastes, and the less curative time in patients. At this moment, other antimalarial drugs must be chosen as replacements for PS or CQ treatment.

As resistance to anti-malarial mono-therapy becomes a serious problem, chemotherapeutic strategy for control of malaria caused by a parasite should be reconsidered. Combination therapy with drugs having different mechanisms of act and biological target in this parasite may be way out (149). It is imminent to make good study design for quickly examining efficacy of two or more anti-malarial drugs in combination. The main aims of the present study are to compare the therapeutic efficacies of mono-therapy using CQ or AQ with those of the combination of CQ or AQ with PS, and to determine which combination is the better efficacy to malaria in the treatment of CQ-resistant infections (22,124,150).
Other measures in malaria control are to prevent mosquito bite in addition to intake of anti-malaria drugs. *Anopheles* mosquitoes are main vector of malaria pathogens. At least fifty *Anopheles* species contribute to transmit these pathogens. Population can avoid malaria infection by eradication of mosquitoes. Mosquito prevention and control methods prevail in many articles. At present, many mosquito controls are divided into chemical measurement, biological treatment, habitat management and application of appliance for prevention and control in mosquito bite and annoyance, such as bed-net, mosquito-killer magnet. These control measures are usually used in combination (IPM, Integrated Pest Management). If persons achieved no mosquito bite by these methods, malaria will end among them.

**Conclusion**

To date, PS and CQ can also be used to fight against malaria in some areas. However, PS showed higher therapeutic efficacy to falciparum malaria in less-than-5-year children than CQ in our systematic review.

**Acknowledgement**

The authors declare that there is no conflict of interest. A special thank to many reviewers for their carefully reviewing and revising the manuscript.

**References**

1. Sachs J, Malaney P. The economic and social burden of malaria. Nature. 2002; 415(6872): 680-5.
2. Guinvoart C, Navia MM, Tanner M, Alonso PL. Malaria: burden of disease. Curr Mol Med. 2006; 6(2):137-40.
3. WHO Media center. The top 10 causes of death.2011; http://www.who.int/mediacentre/factsheets/fs310/en/index.html [accessed on June 2011].
4. WHO Global Health Observatory Data Repository. Millennium Developmental Goals 6: HIV/AIDS, malaria and other diseases, death due to malaria. 2008; http://apps.who.int/ghodata/?vid=490#.
5. Sabbatani S, Fiorino S, Manfredi R. The emerging of the fifth malaria parasite (*Plasmodium knowlesi*), A public health concern. Braz J Infect Dis. 2010; 14(3):299-309.
6. WHO African Region Programmes and projects. Country antimalarial drug policies: by African Region.2011; http://www.who.int/malaria/am_drug_policies_by_region_afro/en/ [last updated on February 2011].
7. WHO South-East Asia Region Programmes and projects. Country antimalarial drug policies: by South-East Asia Region. 2011; http://www.who.int/malaria/am_drug_policies_by_region_searo/en/index.html [last updated on February 2011].
8. WHO European Region Programmes and projects. Country antimalarial drug policies: by European Region. 2011; http://www.who.int/malaria/am_drug_policies_by_region_euro/en/index.html [last updated on February 2011].
9. WHO Western Pacific Region Programmes and projects. Country antimalarial drug policies: by Western Pacific Region. 2011; http://www.who.int/malaria/am_drug_policies_by_region_wpro/en/index.html [last updated on February 2011].
10. WHO East Mediterranean Region Programmes and projects. Country antimalarial drug policies: by East Mediterranean Region. 2011; http://www.who.int/malaria/am_drug_policies_by_region_emro/en/index.html [last updated on February 2011].
11. WHO Region of the Americas Programmes and projects. Country antimalarial drug policies: by Region of the Americas. 2009; http://www.who.int/malaria/am_drug_policies_by_region_amro/en/index.html [last updated on September 2009].
12. Pukrittayakamee S, Supanaranond W, Looareesuwan S, Vanijanonta S, White NJ. Quinine in severe falciparum malaria: evidence of declining efficacy in Thailand. Trans R Soc Trop Med Hyg. 1994; 88(5):324-7.
13. al-Yaman F, Genton B, Mokela D, Narara A, Raiko A, Alpers MP. Resistance of *Plasmodium falciparum* malaria to amodiaquine, chloroquine and quinine in the Madang Province of Papua New Guinea, 1990–1993. P N G Med J.1996; 39(1):16-22.

14. Mutanda LN. Assessment of drug resistance to malaria parasite in residences of Kampa, Uganda. East Afr Med J. 1999;76(8):421-4.

15. Brasseur P, Kouamouo J, Brandinourst O, Moyou SR, Druihle P. Patterns of in vitro resistance to chloroquine, quinine and mefloquine of *Plasmodium falciparum* in Cameroon in 1985-86. Am J Trop Med Hyg. 1988; 39(2):166-72.

16. Moore DV, Lanier SE. Observations on two *Plasmodium* infections with an abnormal response to chloroquine. Am J Trop Med Hyg. 1961; 10:5-9.

17. Omer AH. Response of *Plasmodium falciparum* in Sudan to oral chloroquine. Am J Trop Med Hyg. 1978; 27(5):853-7.

18. Tin F, Nyunt-Hlaing, Lasserre R. Single-dose treatment of *falciparum* malaria with mefloquin & field studies with different doses in semi-immune adults and children in Burma. Bull World Health Organ.1982; 60(6):913-7.

19. Tin F, Nyunt-Hlaing. Comparative drug trial of a sulfadoxine/pyrimethamine and a sulfalene/pyrimethamine Combination against *Plasmodium falciparum* infections in semi-immune populations of Burma. Southeast Asian J Trop Med Public Health. 1984; 15(2):238-48.

20. Nuwaha F. The challenge of chloroquine-resistant malaria in sub-Saharan Africa. Health Policy Plan. 2001;16(1):1-12.

21. Krogitad DJ. Malaria as a re-emerging disease. Epidemiol Rev. 1996; 18(1):77-89.

22. Sowunmi A. A randomized comparison of chloroquine, amodiaquine and their combination with pyrimethamine-sulfadoxine in the treatment of acute, uncomplicated, *Plasmodium falciparum* malaria in children. Ann Trop Med Parasitol. 2002; 96(3):227-38.

23. van Dillen J, Custers M, Wensink A, Wouters B, van Voorthuizen T, Voom W, Khan B, Muller I, Nevill C. A comparison of amodiaquine and sulfadoxine-pyrimethamine as first-line treatment of falciparum malaria in Kenya. Trans R Soc Trop Med Hyg. 1999; 93(2):185-8.
ment of uncomplicated falciparum malaria. Trans R Soc Trop Med Hyg. 1988; 82(4):530-1.

35. Höfler W. Sulfadoxine-pyrimethamine resistant falciparum malaria from Cambodia. Dtsch Med Wochenschr. 1980; 105(10):350-1.

36. Navaratnam V, Mohamad M, Hussain S, Kumar A, Jamaladin A, Sulaiman I, Mahsufi S, Selliah K. Chemosuppression of malaria by the triple combination mefloquine/ sulfadoxine/ pyrimethamine: a field trial in an endemic area in Malaysia. Trans R Soc Trop Med Hyg. 1989; 83(6):755-9.

37. Elke JM, Simooya OO, Sheth UK, Wemdsorfer WH, Njesanzi EK. A double-blind clinical trial of a combination of mefloquine, sulfadoxine and pyrimethamine in symptomatic falciparum malaria. Bull World Health Organ. 1985; 63(2):339-43.

38. Vestergaard OV. Unsuccessful effect of sulfadoxine-pyrimethamine in the treatment of falciparum malaria in Tanzania. Ugeskr Laeger. 1983; 145(10):751.

39. de Souza JM, Sheth UK, Wemdsorfer WH, Trigg PL. A phase II/III double-blind, dose-finding clinical trial of a combination of mefloquine, sulfadoxine, and pyrimethamine (Fansimel) in falciparum malaria. Bull World Health Organ. 1987; 65(3):357-61.

40. Botero D, Restrepo M, Montoya A. Prospective double-blind trial of two different doses of mefloquine plus pyrimethamine-sulfadoxine compared with pyrimethamine-sulfadoxine alone in the treatment of falciparum malaria. Bull World Health Organ. 1985; 63(4):731-7.

41. Miller KD, Lobel HO, Satriale RF, Kuritsky JN, Stern R, Campbell CC. Severe cutaneous reactions among American travelers using pyrimethamine-sulfadoxine (Fansidar) for malaria prophylaxis. Am J Trop Med Hyg. 1986; 35(3):451-8.

42. Darlow B, Vrbowa H, Gibney S, Jolley D, Stace, J, Alpers M. Sulfadoxine-pyrimethamine for the treatment of acute malaria in children in Papua New Guinea. I. Plasmodium falciparum. Am J Trop Med Hyg.1982; 31(1):1-9.

43. Darlow B, Vrbowa H, Gibney S, Jolley D, Stace J, Alpers M. Sulfadoxine-pyrimethamine for the treatment of acute malaria in children of Papua New Guinea. II. Plasmodium vivax. Am J Trop Med Hyg.1982; 31(1):10-3.

44. Li GQ, Arnold K, Guo XB, Jian HX, Fu LC. Randomised comparative study of mefloquine, qinghaosu, and pyrimethamine-sulfadoxine inpatients with falciparum malaria. Lancet. 1984; 2(8416):1360-1.

45. Hurwitz ES, Johnson D, Campbell CC. Resistance of Plasmodium falciparum malaria to sulfadoxine-pyrimethamine (Fansidar) in a refugee camp in Thailand. Lancet. 1981; 1(8229):1068-70.

46. Meek SR, Doberstyn EB, Gaüzère BA, Thanapanich C, Nordlander E, Phuphasian S. Treatment of falciparum malaria with quinine and tetracycline or combined mefloquine-sulfadoxine/ pyrimethamine on the Thai-Kampuchean border. Am J Trop Med Hyg. 1986; 35(2):246-50.

47. Watkins WM, Mosobo M. Treatment of Plasmodium falciparum malaria with pyrimethamine-sulfadoxine: selective pressure for resistance is a function of long elimination half-life. Trans R Soc Trop Med Hyg. 1993; 87(1):75-8.

48. Dinis DV, Schapira A. Comparative study of sulfadoxine-pyrimethamine and amodiaquine + sulfadoxine-pyrimethamine for the treatment of malaria caused by chloroquine-resistant Plasmodium falciparum in Maputo, Mozambique. Bull Soc Pathol Exot. 1990; 83(4):521-8.

49. Mulenga M, Sukwa TY, Canfield CJ, Hutchison DB. Atovaquone and proguanil versus pyrimethamine-sulfadoxine for the treatment of acute falciparum malaria in Zambia. Clin Ther. 1999; 21(5):841-52.

50. Mharakurwa S, Mugooci T. Response of chloroquine-resistant falciparum malaria to sulfadoxine/pyrimethamine in Gokwe area of Zimbabwe. Cent Afr J Med. 1994; 40(3):53-6.

51. Irare SG, Lennge MM, Mhina JI. Falciparum malaria fully cleared by amodiaquine, pyrimethamine/sulfadoxine and pyrimethamine-sulfalene in areas of chloroquine resistance in Dodoma, Tanzania. Trop Geogr Med. 1991; 43(4):352-6.

52. Schmidt-Ott R, Luckner D, Lehman LG, Lell B, Matousek P, Greve B, Kremsner PG. Pyrimethamine/sulfadoxine for treating uncomplicated Plasmodium falciparum malaria in young children in Gabon. Trans R Soc Trop Med Hyg. 1997; 91(5):578-9.

53. Doherty JF, Sadiq AD, Bayo L, Allouche A, Olliaro P, Milligan P, von Seidlein L, Pinder M.
A randomized safety and tolerability trial of artesunate plus sulfadoxine-pyrimethamine versus sulfadoxine-pyrimethamine alone for the treatment of uncomplicated malaria in Gambian children. Trans R Soc Trop Med Hyg. 1999; 93(5): 543-6.

54. Ezedinachi E. In vivo efficacy of chloroquine, halofantrine, pyrimethamine-sulfadoxine and qinghaosu (artesunate) in the treatment of malaria in Calabar, Nigeria. Cent. Afr J Med. 1996; 42(4):109-11.

55. Bustos DG, Canfield CJ, Canete-Miguel E, Hutchinson DB. Atovaquone-Proguanil Compared with Chloroquine and Chloroquine-Sulfadoxine-Pyrimethamine for Treatment of Acute Plasmodium falciparum Malaria in the Philippines. J Infect Dis. 1999; 179(6):1587-1590.

56. Rowland M, Durrani N, Hewitt S, Sondorp E. Resistance of falciparum malaria to chloroquine and sulfadoxine-pyrimethamine in Afghan refugee settlements in western Pakistan: surveys by the general health services using a simplified in vivo test. Trop Med Int Health. 1997; 2(11):1049-56.

57. Garg MR, Gogtay NJ, Kshirsagar NA. Efficacy of sulfadoxine-pyrimethamine in chloroquine resistant falciparum malaria in Bombay. J Assoc Physicians India. 1996; 44(10):683-5.

58. Trinh KA, Nguyen VK, Arnold K, Vo VC, Nguyen NB, Kim T, Ladinsky J. Double-blind studies with mefloquine alone and in combination with sulfadoxine-pyrimethamine in 120 adults and 120 children with falciparum malaria in Vietnam. Trans R Soc Trop Med Hyg. 1990; 84(10):1550.

59. Osorio LE, Giraldo LE, Grajales LF, Arriaga AL, Andrade AL, Ruebush TK, Barat LM. Assessment of therapeutic response of Plasmodium falciparum to chloroquine and sulfadoxine-pyrimethamine in area of low malaria transmission in Colombia. Am J Trop Med Hyg. 1999; 61(6):968-72.

60. Gozal D, Hengy C. Treatment of malaria with sulfadoxine/pyrimethamine: note of caution. Lancet. 1990;336(8707): 111-2.

61. Sowunmi A, Oduola AM. Open comparison of mefloquine, mefloquine/sulfadoxine/pyrimethamine and chloroquine in acute uncomplicated falciparum malaria in children.

62. Mutabingwa TK, Anthony D, Heller A, Hallett R, Ahmed J, Drakeley C, Greenwood BM, Whitby CJ. Amodiaquine alone, amodiaquine+sulfadoxine-pyrimethamine, amodiaquine+artesunate, and artether-lumefantrine for outpatient treatment of malaria in Tanzanian children: a four-arm randomized effectiveness trial. Lancet. 2005; 365(9469):1474-80.

63. Staedke SG, Karnya MR, Dorsey G, Gasasira A, Ndeezzi G, Charlebois ED, Rosenthal PJ. Amodiaquine, sulfadoxine/pyrimethamine, and combination therapy for treatment of uncomplicated falciparum malaria in Kampa, Uganda: a randomised trial. Lancet. 2001; 358(9279):368-74.

64. Depoortere E, Guthmann JP, Pressé J, Siplanyambe N, Nkandu E, Balkan S, de Pécoulas PE, Legros D. Efficacy and effectiveness of the combination of sulfadoxine/pyrimethamine and a 3-day course of artesunate for the treatment of uncomplicated falciparum malaria in a refugee settlement in Zambia. Trop Med Int Health. 2005; 10(2):39-45.

65. Bijl HM, Kager J, Koetsier DW, van der Werf TS. Chloroquine- and sulfadoxine-pyrimethamine-resistant falciparum malaria in vivo - a pilot study in rural Zambia. Trop Med Int Health. 2000; 5(10): 692-5.

66. Barnes KI, Little F, Mabuza A, Mngomezulu N, Govere J, Durrheim D, Roper C, Watkins B, White NJ. Increased gametocytemia after treatment: an early parasitological indicator of emerging sulfadoxine-pyrimethamine resistance in falciparum malaria. J Infect Dis. 2008; 197(11):1605-1613.

67. van Eijk AM, Ouma PO, William J, Ter Kuile FO, Parise M, Otieno K, Hamel MJ, Ayisi JG, Kariuki S, Kager PA, Slutsker L. Plasma folate level and high-dose folate supplementation predict sulfadoxine-pyrimethamine treatment failure in pregnant women in Western Kenya who have uncomplicated malaria. J Infect Dis. 2008; 198(10):1550-3.

68. Happi CT, Ghotosho GO, Folarin OA, Akinbowe DO, Yusuf BO, Ebong OQ, Sowunmi A, Kyle DE, Milhous W, Wirth DF, Oduola AM. Polymorphisms in Plasmodium falciparum dhfr and dhps genes and age related in vivo sulfadoxine-pyrimethamine resistance in

Available at: http://ijpa.tums.ac.ir 12
malaria-infected patients from Nigeria. Acta Trop. 2005; 95(3):183-93.

69. Basco LK, Tahar R, Keundjian A, Ringw P. Sequence variations in the genes encoding dihydroprotoerotate synthase and dihydrofolate reductase and clinical response to sulfadoxine-pyrimethamine in patients with acute uncomplicated falciparum malaria. J Infect Dis. 2000; 182(2):624-8.

70. Ngouesse B, Basco LK, Ringwald P, Keundjian A, Blackett KN. Cardiac effects of amodiaquine and sulfadoxine-pyrimethamine in malaria-infected African patients. Am J Trop Med Hyg. 2001; 65(6):711-6.

71. Obonyo CO, Ochieng F, Taylor WR, Ochola SA, Mugitu K, Olliaro P, ter Kuile F, Oloo AJ. Artesunate plus sulfadoxine-pyrimethamine for uncomplicated malaria in Kenyan children: a randomized, double-blind, placebo-controlled trial. Trans R Soc Trop Med Hyg. 2003; 97(5):585-91.

72. Pullman TN, Craige B Jr, Alving AS, Whorton CM, Jones R Jr, Eichelberger L. Comparison of chloroquine, quin-acrine(atabrine), and quinacrine in the treatment of acute attacks of sporozoite-induced vivax malaria(chesson strain). J Clin Invest. 1948; 27(3Pt1): 46-50.

73. Handfield-Jones RP. Chloroquine, proguanil, mepacrine and quinine in the treatment of malaria caused by Plasmodium falciparum. Ann Trop Med Parasitol. 1949; 43(3-4):345-8.

74. Jelliffe DB. The out-patient treatment of malaria with single dose intramuscular chloroquine in a hyper endemic area in West Africa. Trans R Soc Trop Med Hyg.1953; 47(3):235-8.

75. Charles J. J. Comparative assessment of chloroquine and amodiaquine as malaria suppressives in Nigeria. Ann Trop Med Parasitol. 1958; 52(1):55-67.

76. van den Bergh L, Chardome M, Peel E. Suppressive malaria treatment with chloroquine in the Belgian Congo. An Inst Med Trop. 1952; 9(2):571-8.

77. Nelson TL, Conlin GJ. Treatment of malaria in children with chloroquine. Pediatrics. 1950; 5(2):224-7.

78. Harinasuta T, Viravan C, Reid HA. Sulphormethoxine in chloroquine-resistant falciparum malaria in Thailand. Lancet. 1967; 1(7500):1117-9.

79. Pringle G, Lane FC. An apparent decline in the efficacy of small doses of chloroquine in suppressing malaria parasitaemias in semi-immune African schoolchildren. East Afr Med J. 1966; 43(12):575-8.

80. Jeffery GM, Gibson FD. Studies on chloroquine-resistance of Plasmodium falciparum in Upper Volta and Liberia, West Africa. Bull World Health Organ. 1966; 35(3):441-9.

81. Schneider J, Escudie A, Ouedraogo A, Sales P. Chemioprophylaxis of malaria by weekly distributions of chloroquine or a chloroquine-primaquine-pyrimethamine combination. Bull Soc Pathol Exot Filiales. 1962; 55:280-90.

82. Kean BH. Chloroquine-resistant falciparum malaria from Africa. JAMA.1979; 241(4):395.

83. Hennessy WB, Moodie PM, Black RH. Chloroquine-resistant falciparum malaria from Papua New Guinea and its implications for Australia. Med J Aust. 1977; 1(1-2):9-11.

84. Verdrager AJ, Simanjuntak CH, Saroso JS. Chloroquine-resistant falciparum malaria in East Kalimantan, Indonesia. J Trop Med Hyg. 1976; 79(3):58-66.

85. McKelvey TP, Lundie AR, Vanreenen RM, Williams ED, Moore HS, Thomas MJ, Worsley DE, Crawford IP. Chloroquine-resistant falciparum malaria among British Service Personnel in West Malaysia and Singapore. Trans R Soc Trop Med Hyg. 1971; 65(3):286-304.

86. Rollo IM. Antiplasmodial efficacy of 2,4-diaminopyrimidine-sulfonamide combinations, especially against chloroquine-resistant malaria. Can Med Assoc J. 1975; 112(13):50-3.

87. Powers KG, Jacobs RL. Activity of two chlorinated lincomycin analogues against chloroquine-Resistant falciparum Malaria in owl monkeys. Antimicrob Agents Chemother. 1972; 1(1):49-53.

88. Willerson D Jr, Rieckmann KH, Carson PE, Frischer H. Effects of minocycline against chloroquine-resistant falciparum malaria. Am J Trop Med Hyg. 1972; 21(6):857-62.

89. Ponnampalam JT. A comparative study of malaria prophylaxis in peninsular Malaysia using chloroquine and a combination of sulphadoxine and pyrimethamine. Am J Trop Med Hyg. 1978; 81(10):198-203.

90. Hall AP. Letter: Quinine and chloroquine antagonism in falciparum malaria. Trans R Soc Trop Med Hyg. 1973; 67(3):425.

91. Howells RE, Peters W, Homewood CA, Warhurst DC. Theory for the Mechanism of
Chloroquine Resistance in Rodent Malaria. Nature. 1970; 228(5272):625-8.
92. Finch CD. Chloroquine susceptibility in malaria: Dependence on exposure of parasites to the drug. Life Sci. 1977; 21(10):1511-4.
93. Homwood CA, Warhurst DC, Baggaley VC. A physico-chemical explanation for the clumping of malaria pigment by chloroquine. Trans R Soc Trop Med Hyg. 1971; 65(4):423-4.
94. Siu PM. Malaria: the effect of iron and chloroquine on the erythrocytic forms of Plasmodium berghei. Exp Biol Med. 1972; 139(3):799-802.
95. Védy MJ. Retinopathy caused by chloroquine in the prevention of malaria in children. Bull Soc Ophthalmol Fr. 1975; 75(5-6):609-11.
96. Talib VH, Kiran PC, Talib NJ, Choudhury M. Chloroquine-resistant Plasmodium vivax malaria in infancy and childhood. Indian J Pediatr. 1979; 46(376):158-62.
97. Shirley JA, Eykyn SJ, Pearson TC. Chloroquine-resistant falciparum malaria in a Bangladeshi girl with acute lymphoblastic leukaemia. Br Med J. 1979; 2(6194):834-5.
98. Karstorp A, Fern gren H, Lundbergh P, Lying-Tunell U. Chloroquine-induced neuropathy during malaria suppression. Lakartidningen, 1974; 71(8);679-80.
99. Chovet M, Védy J, Fauxpoint B, Vingtain P. A case of chloroquine retinopathy during malaria prophylaxis in an adult. Rev Int Trach Pathol Ocul Trop Subtrop. 1979; 56(3-4);91-8.
100. Weniger BG, Blumberg RS, Campbell CC, Jones TC, Mount DL, Friedman SM. High-level chloroquine resistance of Plasmodium falciparum malaria acquired in Kenya. N Engl J Med. 1982; 307(25):1500-2.
101. Thapa BR, Mehta S, Singh LM. Complicated chloroquine-resistant malaria. Indian J Pediatr. 1985; 52(415):209-12.
102. Alvar J, Blazquez J, Zubillaga G, Sagredo R, Larruscan F. Chloroquine-resistant falciparum malaria imported into Spain from Malawi. Trans. R. Soc. Trop Med Hyg. 1985; 79(3):419.
103. Wetterey JC, de Geus A. Chloroquine-resistant Plasmodium falciparum malaria in the Netherlands. Bull World Health Organ. 1985; 63(1):101-8.
104. Watkins WM, Oloo AJ, Mjomba M, Koech DK, Gilles HM. Chloroquine-resistant falciparum malaria: Responsiveness to treatment with halofantrine. Parasitology Today. 1989; 5(suppl):45-52.
105. Bitonti AJ, Sjoerdsm A, McCann PP, Kyle DE, Oduola AM, Rossan RN, Milhous WK, Davidson DE Jr. Reversal of chloroquine resistance in malaria parasite Plasmodium falciparum by desipramine. Science. 1988; 242(4883):1301-3.
106. Finch CD. Ferriprotoporphyrin IX: role in chloroquine susceptibility and resistance in malaria. Prog Clin Biol Res. 1989; 313:45-52.
107. Yayon A, Cabantchik ZI, Ginsburg H. Susceptibility of human malaria parasites to chloroquine is pH dependent. Proc Natl Acad Sci USA. 1985; 82(9):2784-8.
108. Ye ZG, van Dyke K. Reversal of chloroquine resistance in falciparum malaria independent of calcium channels. Biochem Biophys Res Commun. 1988; 155(1):476-81.
109. Osifo NG. Chloroquine-induced pruritus among patients with malaria. Arch Dermatol. 1984; 120(1):80-2.
110. Caussade P. Pruritus induced by chloroquine during the treatment of malaria. Arch Fr Pediatr. 1984; 41(10):727.
111. Basco LK, Ringwald P. Molecular epidemiology of malaria in Yaoundé, Cameroon. III. Analysis of chloroquine resistance and point mutations in the multidrug resistance 1 (pfmdr 1) gene of Plasmodium falciparum. Am J Trop Med Hyg. 1998; 59(4):577-81.
112. Rubio JP, Cowman AF. Plasmodium falciparum: the pfmdr2 protein is not overexpressed in chloroquine-resistant isolates of the malaria parasite. Exp Parasitol. 1994; 79(2):137-47.
113. Basco LK, Ringwald P. Molecular epidemiology of malaria in Yaoundé, Cameroon. V. Analysis of the omega repetitive region of the Plasmodium falciparum CG2 gene and chloroquine resistance. Am J Trop Med Hyg. 1999; 61(5):807-13.
114. Sarin K, Kumar A, Prakash A, Sharma A. Oxidative stress and antioxidant defence mechanism in Plasmodium vivax malaria before and after chloroquine treatment. Indian J. Malarial. 1993; 30(3);127-33.
115. Chandra S, Dhawan BN. Reversal of chloroquine resistance in murine malaria parasites by prostaglandin derivatives. Am J Trop Med Hyg. 1993; 48(5):645-51.
116. Markson PG, Winkler S, Brandts C, Graninger W, Bienzle U. Curing of chlo-
roquine-resistant malaria with clindamycin. Am J Trop Med Hyg. 1993; 49(5):650-4.
117. Warhurst DC. A molecular marker for chloroquine-resistant falciparum malaria. N Engl J Med. 2001; 344(9):299-302.
118. Fitch CD, Chen YF, Cai GZ. Chloroquine-induced masking of a lipid that promotes ferritoporphyrin IX dimerization in malaria. J Biol Chem. 2003; 278(25):22596-9.
119. Nomura T, Carlton JM, Baird JK, del Portillo HA, Fryauff DJ, Rathore D, Fidock DA, Su X, Collins WE, McCutchan TF, Wootten JC, Wellems TE. Evidence for different mechanisms of chloroquine resistance in 2 Plasmodium species that cause human malaria. J Infect Dis. 2001; 183(11):1653-61.
120. Laufer MK, Takala-Harrison S, Dzinjalamala FK, Stine OC, Taylor TE, Plowe CV. Return of chloroquine-susceptible falciparum malaria in Malawi was a reexpansion of diverse susceptible parasites. J Infect Dis. 2010; 202(5):801-8.
121. Wangai LN, Kimani FT, Omar SA, Karanja SM, Nderu DWG, Mutua D. Chloroquine resistance status a decade after national drug policy change. Trop Med Int Health. 2004; 9(11):1184-90.
122. Kazadi WM, Vong S, Makina BN, Mantshamba JC, Kabuya W, Kebela B, Ngimbi NP. Assessing the efficacy of chloroquine and sulfadoxine-pyrimethamine for treatment of uncomplicated Plasmodium falciparum malaria in the Democratic Republic of Congo. Trop Med Int Health. 2003; 8(10):868-75.
123. Radiguès X, Diallo KI, Diallo M, Navakum PA, Maiga H, Djjimdé A, Sacko M, Dourombo O, Guthmann JP. Efficacy of chloroquine and sulfadoxine/pyrimethamine for the treatment of uncomplicated Plasmodium falciparum malaria in Koumantou, Mali. Trans R Soc Trop Med Hyg. 2006; 100(11):1013-8.
124. Stirvelo E, Cavalleri P, Cassano F, Omar S.A., Kariuki D, Mwangi J, Piola P, Guthman JP. Efficacy of chloroquine, sulfadoxine–pyrimethamine and amodiaquine for treatment of uncomplicated Plasmodium falciparum malaria in Kajo Keji county, Sudan. Trop Med Int Health. 2004; 9(9):975-80.
125. Guthmann JP, Ampuero J, Fortes F, Overmeir C, Gaboulaud V, Tobbac S, Dunand J, Sarava N, Gillot P, Franco J, Denoncin A, Herp M, Balkan S, Dujardin JC, Alessandro UD, Legros D. Antimalarial efficacy of chloroquine, amodiaquine, sulfadoxine-pyrimethamine, and the combination of amodiaquine+artesunate and sulfadoxine-pyrimethamine+artesunate in Huambo and Bié provinces, central Angola. Trans. R. Soc. Trop. Med. Hyg. 2005; 99(7):485-92.
126. Abacassamo F, Enoosse S, Aponte JJ, Gómez-Olivé, FX, Quintó I., Mabunda S, Barreto A, Magnussen P, Ronn AM, Thompson R, Alonso PL. Efficacy of chloroquine, amodiaquine, sulfadoxine-pyrimethamine and combination therapy with artesunate in Mozambican children with non-complicated malaria. Trop Med Int Health. 2004; 9(2):200-8.
127. Grandesso F, Bachy C, Donan I, Ndamb J, Habimana J, Alessandro UD, Maikere J, Vanlerberge V, Kerah CH, Guthmann JP.
Efficacy of chloroquine, sulfadoxine-pyrimethamine and amodiaquine for treatment of uncomplicated *Plasmodium falciparum* malaria among children under five in Bongor and Koumra, Chad. Trans R Soc Trop Med Hyg. 2006; 100(5):419-26.

132. Legros D, Johnson K, Houplikian P, Makanga M, Kabakengya JK, Talisuna AO, Taylor WRJ. Clinical efficacy of chloroquine or sulfadoxine-pyrimethamine in children under five from south-western Uganda with uncomplicated falciparum malaria. Trans R Soc Trop Med Hyg. 2002; 96(2):199-201.

133. Kaland GC, Hill J, Verhoef FH, Brabin BJ. Comparative efficacy of chloroquine and sulfadoxine-pyrimethamine in pregnant women and children: a meta-analysis. Trop Med Int Health. 2006; 11(5):569-77.

134. WHO. Assessment and monitoring of anti-malarial drug efficacy for the treatment of uncomplicated falciparum malaria. World Health Organization, Geneva, 2003; WHO/HTM/RBM/2003.50.

135. Aubouy A, Fivet N, Bertin G, Sagbo JC, Kossoh H, Kinde-Gazard D, Kiniffo R, Massougbodji A, Deloron P. Dramatically decreased therapeutic efficacy of chloroquine and sulfadoxine-pyrimethamine, but not mefloquine, in southern Benin. Trop Med Int Health. 2007; 12(7):886-94.

136. Ndyomugenyi R, Magnussen P. In vivo sensitivity of *Plasmodium falciparum* to chloroquine and sulfadoxine-pyrimethamine in school children in Hoima district, western Uganda. Acta Trop. 1997; 66(3):137-43.

137. Rahman M, Rahman R, Bangali M, Das S, Talukder MR, Ringwald P. Efficacy of combined chloroquine and sulfadoxine-pyrimethamine in uncomplicated *Plasmodium falciparum* malaria in Bangladesh. Trans R Soc Trop Med Hyg. 2004; 98(7):438-41.

138. Warsame M, Abdillahi A, Duale ON, Ismail NA, Hassan AM, Mohamed A, Warsame A. Therapeutic efficacy of chloroquine and sulfadoxine/pyrimethamine against *Plasmodium falciparum* infection in Somalia. Bull World Health Organ. 2002; 80(9):704-8.

139. Sutanto I, Supriyanto S, Rickert PP, Maguire JD, Bangs MJ. Comparative efficacy of chloroquine and sulfadoxine-pyrimethamine for uncomplicated *Plasmodium falciparum* malaria and impact on gametocyte carriage rates of

in the east Nusatenggara province of Indonesia. Am J Trop Med Hyg. 2004; 70(5):467-73.

140. Marquino W, Macarthur JR, Barat LM, Oblitas FE, Arrunategui M, Garavito G, Chalfoque ML, Pardavé B, Gutierrez S, Arrósipide N, Carrillo C, Cabezas C, Ruebush TK. Efficacy of chloroquine, sulfadoxine-pyrimethamine, and mefloquine for treatment of uncomplicated *Plasmodium falciparum* malaria on north coast of Peru. Am J Trop Med Hyg. 2003; 68(1):120-3.

141. Osorio LE, Ferro BE, Castillo CM. Effects of chloroquine and sulfadoxine/pyrimethamine on gametocytes in patients with uncomplicated *Plasmodium falciparum* malaria in Colombia. Mem Inst Oswaldo Cruz. 2002; 97(8):1221-3.

142. Kofoed PE, Rodrígues A, Aaby P, Rombo L. Continued efficacy of sulfadoxine-pyrimethamine as second line treatment for malaria in children in Guinea-Bissau. Acta Trop. 2006; 100(3):213-7.

143. Broek IVF, Gatkoii T, Lowoko B, Nizila A, Ochong E, Keus K. Chloroquine, sulfadoxine-pyrimethamine and amodiaquine efficacy for the treatment of uncomplicated *Plasmodium falciparum* malaria in Upper Nile, South Sudan. Trans R Soc Trop Med Hyg. 2003; 97(2):229-35.

144. Aziken ME, Akubuo KK, Gharoro EP. Efficacy of intermittent preventive treatment with sulfadoxine-pyrimethamine on placental parasitemia in pregnant women in midwestern Nigeria. Int J Gynaecol Obstet. 2011; 112(1):30-3.

145. Shiff C. Efficacy of sulfadoxine-pyrimethamine as the first line treatment for malaria declining in Malawi. Evidence-based Healthcare and public health. 2004; 8(5):280-3.

146. Mayxay M, Phetsouvanh R, Phompida S, Newton PN, Khanthavong M, Vannachone B, Brockman A, White NJ. A randomized comparison of oral chloroquine and sulfadoxine-pyrimethamine for the treatment of uncomplicated *Plasmodium falciparum* malaria in Laos. Trans R Soc Trop Med Hyg. 2003; 97(3):343-4.

147. Zakeri S, Farahani MS, Afsarpad M, Salehi M, Raei A, Djadid ND. High prevalence of the 437G mutation associated with sulfadoxine resistance among *Plasmodium falciparum* clinical isolates from Iran, three years after the introduction of sulfadoxine-pyrimethamine. Int J Infect Dis. 2010; 14(sup3):e123-128.
148. Rieckmann K, Cheng Q. Pyrimethamine-sulfadoxine resistance in *Plasmodium falciparum* must be delayed in Africa. Trends Parasitol. 2002; 18(7):293-4.

149. White N. Antimalarial drug resistance and combination chemotherapy. Philos Trans R Soc Lond B Biol Sci. 1999; 354(1384):739-49.

150. Ndyomugenyi R, Magnussen P, Clarke S. The efficacy of chloroquine, sulfadoxine-pyrimethamine and a combination of both for the treatment of uncomplicated *Plasmodium falciparum* malaria in an area of low transmission in western Uganda. Trop Med Int Health. 2004; 9(1):47-52.